Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $2.8 million.

  • Atara Biotherapeutics' Prepaid Assets fell 6950.57% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 6950.57%. This contributed to the annual value of $10.1 million for FY2024, which is 6356.73% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Prepaid Assets is $2.8 million, which was down 6950.57% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Prepaid Assets ranged from a high of $16.0 million in Q3 2022 and a low of $2.4 million during Q2 2025
  • Moreover, its 4-year median value for Prepaid Assets was $9.4 million (2023), whereas its average is $8.9 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Prepaid Assets soared by 6356.73% in 2024, and later tumbled by 6950.57% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Prepaid Assets (Quarter) stood at $10.3 million in 2022, then crashed by 40.01% to $6.2 million in 2023, then surged by 63.57% to $10.1 million in 2024, then tumbled by 72.25% to $2.8 million in 2025.
  • Its Prepaid Assets stands at $2.8 million for Q3 2025, versus $2.4 million for Q2 2025 and $4.3 million for Q1 2025.